A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 100 participants.
Also called NCT01785771
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT01785771
-
- Other papers using this trial's data
- Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT01785771. Allocation not applicable; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2018-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- ITCA 650 (exenatide in DUROS)
- Lead sponsor
- Intarcia Therapeutics
Record details
- Record id
cardio:ct-nct01785771- Content hash
867af78e2d0b4fcd28439867f96f5d5b54ab3a3a5b3b97ab22efc3681e741670